# STCube

Source: https://onco.cc/companies/stcube/  
OnCo record `stcube` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

STCube is a South Korea-based biotechnology company running 2 late-stage cancer trials of Nelmastobart in non-small-cell lung cancer and colorectal cancer.

## Summary

STCube, based in Seoul, South Korea, is a biotechnology company. STCube (STCube Pharmaceuticals) develops immunotherapy drugs targeting novel immune checkpoints, with a lead focus on inhibiting BTN1A1 in cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Nelmastobart in non-small-cell lung cancer and colorectal cancer. The largest, NCT07306624 (Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer), plans to enrol 62 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: STCube, Inc.
- Tags: ctgov-sponsor
- HQ: Seoul
- Type: biotech
- Website: https://www.stcube.com/

## Sources

- Official website: https://www.stcube.com/
- ClinicalTrials.gov: trials led by STCube: https://clinicaltrials.gov/search?lead=STCube%2C%20Inc.

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- trials: [Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer](https://onco.cc/trials/nct07306624/), [Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer](https://onco.cc/trials/nct06873763/)

---
JSON: https://onco.cc/api/v1/entities/stcube.json